Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 4/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.51 |
| ▸ | CPA1 | P15085 | 4/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.50 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704073 | 1.00 | CTSC (0.54) | CTSCCYP1A2CYP3A4CTSHCYP2D6 | |
| SCHEMBL7648961 | 0.90 | SLC7A5 (0.63) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL989802 | 0.90 | SLC7A5 (0.63) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL583592 | 0.90 | SLC7A5 (0.63) | CTSCALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL1262434 | 0.88 | SLC7A5 (0.61) | CTSCALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6164804 | 0.88 | SLC7A5 (0.61) | CTSCALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6164795 | 0.88 | SLC7A5 (0.61) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL14123988 | 0.86 | OPRD1 (0.53) | CTSCCYP1A2CYP3A4CTSHCYP2D6 | |
| SCHEMBL12377253 | 0.84 | CTSC (0.59) | CTSCCYP1A2CYP3A4CTSHCYP2D6 | |
| SCHEMBL18554025 | 0.84 | CTSC (0.59) | CTSCCYP1A2CYP3A4CTSHCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2640689-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| CN-103249715-A | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP inhibitors | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| US-5700838-A | Hydroxamic acid derivatives as metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0651739-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1997-04-09 | — | — | EP | disclosed |
| EP-0754688-A2 | Dioxolane intermediates | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-01-22 | — | — | EP | disclosed |
| EP-0651739-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS. | BRITISH BIOTECH PHARM (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002447-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CTSC 71/4885CYP1A2 1025/4885CYP3A4 1140/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | CTSC 1384/4885CYP1A2 24/4885CYP3A4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.